Tazopenil

Active substance

Piperacillin/Tazobactam

Strenght and pharmaceutical forms

2 g / 0.25 g/4 ml powder and solvent for injectable solution for intramuscular use
4 g / 0.5 g powder for solution for infusion - 1 / 10 vials

ATC

J01C R05 - Antibacterials for systemic use. Combination of penicillins incl. beta-lactamases inhibitors

Therapeutic Indications

TAZOPENIL is indicated for treatment of the following infections in adults and children over 2 years of age:

Adults and adolescents
- Severe pneumonia including hospital-acquired and ventilator-associated pneumonia
- Complicated urinary tract infections (including pyelonephritis)
- Complicated intra-abdominal infections
- Complicated skin and soft tissue infections (including diabetic foot infections)
Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Tazopenil may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection.

Children 2 to 12 years of age
- Complicated intra-abdominal infections

Tazopenil may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection

Marketing Authorization Holder

Magis Farmaceutici S.r.l.

Dealership for sale

Aesculapius Farmaceutici S.r.l.

Download area

Summary of Product Characteristics - Tazopenil 2.25g and 4.5g

Summary of Product Characteristics - Tazopenil 4.5g 10 vials